Page 3 - Accelerate Diagnostics News Today

StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research note released on Wednesday morning. The firm issued a hold rating on the medical research company’s stock. Accelerate Diagnostics Trading Down 5.2 % NASDAQ:AXDX opened at $1.28 on Wednesday. The stock has a market capitalization of $18.65 million, a price-to-earnings […]

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.18% to 37,536.76 while the NASDAQ rose 0.38% to 15,113.04. The S&P 500 also rose, gaining, 0.19% to 4,790.00.

Accelerate Diagnostics, Inc. (AXDX) Friday announced the pricing of its offering of $15 million of shares and in lieu of common stock to certain investors, pre-funded warrants to purchase shares.

Accelerate Diagnostics, Inc. (AXDX) Friday announced the pricing of its offering of $15 million of shares and in lieu of common stock to certain investors, pre-funded warrants to purchase shares.

TUCSON, Ariz., Jan. 16, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of...

Accelerate Diagnostics Stock (NASDAQ: AXDX) stock price, news, charts, stock research, profile.

Accelerate Diagnostics Inc. (AXDX) reported that its preliminary revenue for the fiscal year 2023 declined to about $12.1 million from last year's $12.8 million, due to a challenging capital sales environment in all sales regions.

TUCSON, Ariz., Jan. 7, 2024 /PRNewswire/ --  Accelerate Diagnostics, Inc. , an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs...

Equities research analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a report released on Thursday. The brokerage set a “hold” rating on the medical research company’s stock. Several other brokerages also recently commented on AXDX. William Blair reiterated an “outperform” rating on shares of Accelerate Diagnostics in […]

Cytovale, a San Francisco-based medical diagnostics company, raised $84 million in Series C funds to advance the commercialization of its diagnostic test for early sepsis detection. Using standard blood draws, the test provides results in under 10 minutes. It is meant to detect sepsis in patients who present to hospital emergency departments.